

ARTICLE



# Prevalence, Antimicrobial Resistance, and Distribution of blaCTX-M and blaTEM Genes Among ESBL-Producing *Morganella morganii* Isolated from Clinical Samples in Bangladesh

Arifuzzaman\*<sup>1</sup>, Faizur Rahman<sup>2</sup>, Asaduzzaman<sup>2</sup>, Avizit Sarker<sup>2</sup>

<sup>1</sup> Department of Microbiology, Khulna City Medical College, Khulna

<sup>2</sup> Department of Microbiology, Dhaka Medical College, Dhaka

## ABSTRACT

**Background:** *Morganella morganii*, once regarded as a benign intestinal commensal, now poses a serious threat due to its intrinsic AmpC  $\beta$ -lactamase production and increasing multidrug resistance. **Objective:** This study aimed to assess the efficacy of antibiotic combination therapies against MDR *Morganella morganii* isolates, specifically evaluating ceftazidime plus amikacin and amikacin plus imipenem regimens to improve treatment outcomes. **Methods:** A cross-sectional observational and experimental study was conducted from November 2022 to June 2023 at Dhaka Medical College Hospital, Bangladesh. Seven clinical *Morganella morganii* strains were isolated from urine, wound, blood, and stool samples. Identification was performed using culture, biochemical tests, and PCR. Antimicrobial susceptibility was determined by disc diffusion and MIC via agar dilution following CLSI (2022) guidelines using standard protocols. **Results:** Seven isolates of *Morganella morganii* were recovered, representing an overall prevalence of 1.72%. Urine samples yielded 42.85% of isolates, while wound samples contributed 28.57%. Males accounted for 71.42% of cases, predominantly in the 26–35-year age group. ESBL production was observed in 28.57% of isolates, with PCR confirming bla<sub>CTX-M</sub> and bla<sub>TEM</sub> genes in 50% each among ESBL-positive strains. Carbapenemase production was detected in 50% and 25% of imipenem-resistant isolates by CD assay and DDS test, respectively. Overall, 57.14% were MDR and 14.28% XDR. Detailed calculations indicate significant associations between risk factors and resistance patterns with high significance. **Conclusion:** This study underscores the urgent need for early detection and targeted combination therapy to combat MDR and XDR *Morganella morganii*, with ceftazidime-amikacin and amikacin-imipenem regimens showing promising clinical potential.

**Keywords:** Prevalence, Antimicrobial Resistance, bla<sub>CTX-M</sub> and bla<sub>TEM</sub> Genes, *Morganella morganii*

| Submitted: 16.12.2024 | Accepted: 22.02.2025 | Published: 28.02.2025

### \*Corresponding Author

Dr. Arifuzzaman

### How to Cite the Article

Arifuzzaman, Faizur Rahman, Asaduzzaman, Avizit Sarker. Prevalence, Antimicrobial Resistance, and Distribution of bla<sub>CTX-M</sub> and bla<sub>TEM</sub> Genes Among ESBL-Producing *Morganella morganii* Isolated from Clinical Samples in Bangladesh. *IAR J Med Surg Res.* 2025; 6 (1): 34–42.



© 2025 IAR Journal of Medicine and Surgery Research, a publication of JMSRP Publisher, Kenya.

This is an open access article under the terms of the Creative Commons Attribution license.

(<http://creativecommons.org/licenses/by/4.0>).

(<https://jmsrp.or.ke/index.php/jmsrp>).

## INTRODUCTION

*Morganella morganii* is a gram-negative bacillus belonging to the Enterobacteriaceae family, and it is a common inhabitant of the environment and intestinal tracts of humans, mammals, and reptiles [1]. *Morganella morganii* is recognized as an unusual opportunistic pathogen that is isolated specifically in urinary tract or wound infections. However, *Morganella morganii* has recently been regarded as an increasingly important pathogenic bacterium due to

its virulence and increased drug resistance, which causes a variety of clinical infections, such as urinary tract infections, bacteremia and sepsis, and results in a high mortality rate in some infections [2]. Biologically, *Morganella morganii* is a motile, non-lactose fermenting bacterium, which shares with the *Proteus* members the capacity for urease production and the presence of phenylalanine deaminase<sup>3</sup>. *Morganella morganii* is an unusual opportunistic pathogen that is clinically and often isolated as a cause of nosocomial infection in adults, specifically in urinary tract or wound infections.

The urinary tract is the major portal for *Morganella morganii* entry, followed by the hepatobiliary tract, skin and soft tissue, and blood [3]. A variety of virulence factors including fimbrial adhesins, lipopolysaccharides (LPS), IgA protease, hemolysins, ureases, insecticidal and apoptotic toxins, iron acquisition system, type-III secretion system, and two-component systems allows *Morganella morganii* to cause various invasive infections [4]. *Morganella morganii* has chromosomally encoded *blaAmpC*, which confers resistance to cephalosporins and penicillins [5]. As a result of its ability to cause invasive disease, the presence of *blaAmpC* and virulence factors, and its propensity to acquire resistance determinants, *Morganella morganii* has been labeled an emerging “superbug” [6]. Enterobacterales resistant to third-generation cephalosporins due to the production of AmpC  $\beta$ -lactamase encoded by resident chromosomal genes (e.g., *Enterobacter* spp., *Serratia marcescens*, *Citrobacter freundii*, *Providencia* spp., *Morganella morganii* – ESCPM group) are frequent agents of bloodstream infection. In the ESCPM group, AmpC  $\beta$ -lactamase can be expressed at high levels by mutation. Overexpression confers resistance to broad-spectrum cephalosporins including cefotaxime, ceftazidime, and ceftriaxone [7]. AmpC expression among these organisms is inducible in response to  $\beta$ -lactam exposure. On removal of  $\beta$ -lactam exposure, AmpC production generally decreases; however, if mutations have occurred in certain regulatory genes (e.g., *ampD*, *ampR*), selection of mutants with stable AmpC de-repression can occur [8].

Antimicrobial resistance in *Morganella morganii* has been mainly acquired via plasmids and class 1 integrons. Enzymes conferring resistance to beta-lactams and carbapenems, such as TEM, CTX-M, KPC, OXA, VIM, and NDM, have been detected in clinical isolates of *Morganella morganii*, representing a challenge to therapeutic success [9]. The wide spectrum of  $\beta$ -lactamases represented by TEM-1 and SHV-1 gave rise to the name “extended spectrum”  $\beta$ -lactamases (ESBL), which later involved CTX-M and OXA-type enzymes. These enzymes are capable of hydrolyzing and inactivating a wide variety of therapeutic  $\beta$ -lactam antimicrobials [10]. MDR and extensively drug-resistant clinical strains of *Morganella morganii* are frequently reported around the globe [11]. The detectable presence of extensively resistant *Morganella morganii* strains exclusively on the artificial substrate may depict the potential role of plastic in amplifying the pathogenicity of bacteria. Plastics provide a hydrophobic surface for the attachment of microorganisms, promoting colonization and biofilm formation. Under this condition, commonly found on medical implant surfaces, bacteria form a complex and multi-layered three-dimensional architecture, which offers protection from a wide range of environmental challenges and favors the exchange of drug-resistance genes [12].

*Morganella morganii* has developed a remarkable ability to adhere to different surfaces, form biofilms, and acquire highly efficient MDR. In the clinical sector, the biofilm-forming potential of such pathogenic bacteria is a significant problem, which is well documented and refers to hospital-acquired infections transmitted by catheters [13]. Like *Proteus mirabilis*, *Morganella morganii* is a urease-positive organism. However, it produces a urease enzyme that is distinct from that of *Proteus mirabilis*, and the urine pH change mediated by *Morganella morganii* urease activity rarely results in the development of struvite crystals or catheter blockage. *Morganella morganii* is more commonly isolated from unobstructed catheters than blocked catheters in patients catheterized long-term [13]. Urease production serves as a fitness factor that facilitates bacterial growth and biofilm formation during urinary tract infections, which may explain why *Morganella morganii* mainly causes urinary tract infections. *Morganella morganii* utilizes D-serine degradation metabolic pathways to improve its fitness during polymicrobial catheter-associated urinary tract infections (CAUTIs), emphasizing its dominant role in CAUTI in the future [14]. The increasing problem of multidrug-resistant (MDR) bacteria in recent years has created the need to judge and reconsider new antibiotic options for the treatment of these infections [15].

However, monotherapy may lead to the development of resistance and often treatment failure. Combination antimicrobial therapies can be a good alternative. Selecting the appropriate combination therapy is a challenging task in the clinical setting. In this situation, *in vitro* antimicrobial synergy tests can shed valuable light on effective combinations with acceptable/minimal side effects in the management of these difficult-to-treat infections [16]. Animal models are considered the most important *in vivo* models in terms of basic pharmacokinetic parameters like drug efficiency, safety, and toxicological studies, as these pre-clinical data are required before translating into humans. In most instances, both *in vitro* and *in vivo* models are corroborated before proceeding to medical trials. *In vivo* models are mostly conducted in mice, rats, and rabbits [17]. Until better antibiotics are being developed, novel antibiotic combinations that yield some *in vitro* and *in vivo* synergistic activity are perhaps the best options we have to manage this grave condition. No study on *Morganella morganii* has yet been carried out at the microbiology department of DMCH. Therefore, this study has been designed to evaluate the efficacy of antibiotic combinations against multidrug-resistant *Morganella morganii* both *in vitro* and *in vivo*.

## METHODOLOGY

The study was carried out at the Department of Microbiology, Dhaka Medical College, from November 2022 to June 2023, to inquire the prevalence, antimicrobial resistance, and distribution of blaCTX-M and blaTEM genes among ESBL-producing *Morganella morganii* isolates. The sample size was 550, determined based on the estimated infection prevalence. Blood, urine, stool, wound swabs, and pus samples were collected from patients with clinically suspected infections admitted to Dhaka Medical College Hospital. Participants were included regardless of sex or prior antibiotic intake, following informed written consent. Patients unwilling to provide consent were excluded. Data on patient demographics, duration of hospital stay, and laboratory findings were documented on a structured data collection sheet. Sample collection followed strict aseptic protocols. Wound and pus samples were collected with sterile swabs, venous blood was drawn with proper skin disinfection, and midstream clean-catch urine was obtained. Stool samples were collected during acute diarrheal episodes. All samples were promptly sent to the laboratory for examination. In the laboratory, the samples were cultured on blood agar, MacConkey agar, Mueller-Hinton agar, SS agar, and chromogenic agar as required. Biochemical identification was performed by triple sugar iron (TSI) agar, Simmons' citrate agar, and motility-indole-urease (MIU) agar. Automated identification was performed with the VITEK® 2 COMPACT system. Antimicrobial susceptibility testing was performed by Kirby-Bauer disc diffusion method, interpreted according to CLSI guidelines (2022). ESBL-producing organisms were identified by double-disc synergy tests, and MDR and XDR strains were categorized by standard definitions. Checkerboard assays were used for the detection of synergistic interactions between antibiotics and MBL was detected with disc combination assays in addition to EDTA. The method enabled the detection of *Morganella morganii*, confirmed its resistance pattern, and tested potential antibiotic combinations and provided insightful information on antimicrobial stewardship and infection control.

## RESULT

The present study included 550 samples. 205 were urine samples, 148 were wound swabs/pus samples, 80 were blood samples, and 117 were stool samples. Of these, 407 (74%) yielded culture-positive results, as shown in Table 1. Culture yielded growth of 152 (74.14%) in urine samples, followed by 115 (77.71%) in wound swab/pus samples. Table 2 demonstrates the distribution of different species of bacteria isolated from different samples. Among the isolated bacteria, 118 (28.99%) were *Esch. coli*, 7 (1.72%) were *Morganella morganii*. Table 3 shows the distribution of *Morganella morganii* isolated from culture-positive samples. Among the 152 culture-positive urine samples, 3 (1.97%) isolates were *M. morganii*; among 115 culture-positive wound swab/pus samples, 2 (1.74%) isolates were *M. morganii*; among 54 culture-positive blood samples, one (1.85 %) isolated was *M. morganii* and among 86 culture positive stool samples, one (1.16%) isolated was *M. morganii*.

**Table 1: Culture-positive results from various clinical samples (N = 550)**

| Samples            | Number of samples | Culture positive n (%) |
|--------------------|-------------------|------------------------|
| Urine              | 205               | 152 (74.14)            |
| Wound swab and pus | 148               | 115 (77.71)            |
| Blood              | 80                | 54 (67.50)             |
| Stool              | 117               | 86 (73.50)             |
| Total              | 550               | 407 (74.00)            |

N = Total number of samples.

n = number of culture-positive samples.

**Table 2: Distribution of organisms isolated from different samples by biochemical tests (N =407).**

| Organisms             | n (%)        |
|-----------------------|--------------|
| Escherichia coli      | 118 (28.99)  |
| Pseudomonas spp.      | 73 (17.94)   |
| Klebsiella spp.       | 56 (13.76)   |
| Acinetobacter spp.    | 19 (4.67)    |
| Enterobacter spp.     | 41 (10.07)   |
| Citrobacter spp.      | 28 (6.88)    |
| Proteus spp.          | 21 (5.16)    |
| Salmonella spp.       | 6 (1.47)     |
| Staphylococcus aureus | 26 (6.39)    |
| Morganella morganii   | 7 (1.72)     |
| Providencia spp.      | 6 (1.47)     |
| Enterococcus spp.     | 6 (1.47)     |
| Total                 | 407 (100.00) |

N= Total number of bacteria.

n = number of bacterial species.

**Table 3: Distribution of Morganella morganii isolated from different culture-positive samples (N = 407)**

| Source of the samples      | M. morganii n (%) |
|----------------------------|-------------------|
| Urine (N=152)              | 3 (1.97)          |
| Wound swab and pus (N=115) | 2 (1.74)          |
| Blood (N=54)               | 1 (1.85)          |
| Stool (N=86)               | 1 (1.16)          |
| Total                      | 7 (1.72)          |

N = Total number of culture-positive samples.

n = number of isolated M. morganii from different culture-positive samples.

Table 4 demonstrates the distribution of isolated Morganella morganii among in-patient and out-patient departments. Among the 7 M. morganii isolates, 6 (85.71%) were from the in-patient department (from urine, wound swab/pus, blood samples) and one (14.29%) was from the out-patient department (from stool

samples). Table 5 shows the distribution of isolated Morganella morganii according to gender among patients of different age groups. Five were isolated from male and 2 were from female patients. Four (57.14%) were from the age group 61-80 years and 3 (42.86%) were from age group 41-60 years. Table 6 shows the antimicrobial

resistance pattern of the isolated *Morganella morganii*. Among the 7 isolated *M. morganii*, four (57.14%) each were resistant to amikacin and imipenem and 5 (71.42 %) each were resistant to ceftriaxone, ceftazidime, cefepime,

ciprofloxacin, amoxiclav, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, aztreonam, and ceftazidime.

**Table 4: Distribution of isolated *Morganella morganii* among in-patient and out-patient departments (N=7)**

| Isolated <i>M. morganii</i> | n (%)     |
|-----------------------------|-----------|
| In-patient department       | 6 (85.71) |
| Out-patient department      | 1 (14.29) |

**Table 5: Distribution of isolated *Morganella morganii* according to gender among patients of different age groups**

| Age group (In year) | Male (N=5) n (%) | Female (N=2) n (%) | Total (N=7) n (%) |
|---------------------|------------------|--------------------|-------------------|
| 41-60               | 2 (40.00)        | 1 (50.00)          | 3 (42.86)         |
| 61-80               | 3 (60.00)        | 1 (50.00)          | 4 (57.14)         |

**Table 6: Antibiotic resistance pattern of isolated *Morganella morganii* by disc diffusion method (N=7)**


| Antimicrobial drugs           | Resistance, n (%) |
|-------------------------------|-------------------|
| Amoxiclav                     | 5 (71.42)         |
| Ceftriaxone                   | 5 (71.42)         |
| Aztreonam                     | 5 (71.42)         |
| Cefepime                      | 5 (71.42)         |
| Ceftazidime                   | 5 (71.42)         |
| Cefoxitin                     | 5 (71.42)         |
| Piperacillin-tazobactam       | 5 (71.42)         |
| Ciprofloxacin                 | 5 (71.42)         |
| Amikacin                      | 4 (57.14)         |
| Imipenem                      | 4 (57.14)         |
| Trimethoprim-Sulfamethoxazole | 5 (71.42)         |

N = Total number of isolated *M. morganii*.

n = Number of resistant bacteria.

Figure 1 demonstrates ESBL producers among the isolated *Morganella morganii*. Among 7 isolated *M. morganii*, 2 (28.57%) were ESBL producers and 5 (71.43%) were non-ESBL producers. Table 7 summarizes the distribution of ESBL-producing *Morganella morganii* in different samples identified by the DDS test. Among 2 ESBL-producing *M. morganii*, one (50%) was detected from urine samples, and one (50%) was detected from

pus/wound swab samples. Table 8 summarizes the distribution of blaCTX-M and blaTEM, genes among phenotypically confirmed ESBL-producing *Morganella morganii* in different samples by PCR. Among the 2 ESBL producers, the blaCTX-M gene was present in one (50%) isolated wound swab/pus sample and the blaTEM gene was present in one (50%) isolated urine sample.



**Figure 1: ESBL producers among the isolated *Morganella morganii* (N=7)**

**Table 7: Distribution of ESBL-producing *Morganella morganii* identified by DDS test (N=2) *Morganella morganii* in different samples (N=2)**

| Samples          | n (%)     |
|------------------|-----------|
| Urine            | 1 (50.00) |
| Pus & wound swab | 1 (50.00) |

N=Total number of  $\beta$ -lactamase genes.

n=number of different  $\beta$ -lactamase genes.

**Table 8: Distribution of blaCTX-M and blaTEM among phenotypically confirmed ESBL-producing**

| Gene     | Pus and wound swab n (%) | Urine n (%) | Total n (%) |
|----------|--------------------------|-------------|-------------|
| blaCTX-M | 1 (50.00)                | 0 (00.00)   | 1 (50.00)   |
| blaTEM   | 0                        | 1 (50.00)   | 1 (50.00)   |

N=Total number of  $\beta$ -lactamase genes.

n=number of different  $\beta$ -lactamase genes.

## DISCUSSION

*Morganella morganii*, a non-negligible opportunistic pathogen from the Enterobacteriaceae family, has recently been listed by the World Health Organization (WHO) as a global priority pathogen due to its alarming capacity to acquire drug-resistance genes, which leads to increased mortality rates [18]. Antibiotic resistance has emerged as a pressing global health issue over the past two decades, with resistance now affecting a substantial portion of bacteria responsible for hospital-acquired infections. As many as 70% of hospital-acquired infections are caused by bacteria resistant to at least one commonly used antibiotic, with many strains now exhibiting multidrug resistance (MDR) [19]. In Bangladesh, data on *M. morganii* is scarce, with only one study conducted on cattle in Dhaka [20]. The present study aims to highlight the significance of *M. morganii* as an emerging nosocomial pathogen, focusing on its MDR

profile and evaluating potential antibiotic combinations as alternative treatments for this challenging pathogen. In the current study, 74% of the 550 samples yielded culture-positive results. Among these, *Escherichia coli* was the most commonly isolated organism (28.99%), followed by *Pseudomonas* spp. (17.94%), a result consistent with previous findings in Dhaka Medical College Hospital (DMCH) [21]. *M. morganii* showed an overall prevalence of 1.72% among the culture-positive samples, which aligns closely with findings from Taiwan (1.47%) and India (0.89%) [22, 23]. The relatively high prevalence in this study might be attributed to the frequent use of broad-spectrum cephalosporins in hospitalized patients at DMCH, to which *M. morganii* is often resistant due to the presence of chromosomal AmpC  $\beta$ -lactamase. This makes *M. morganii* more prone to cause nosocomial infections. Other studies reporting lower prevalence may stem from difficulties in identifying *M. morganii* in

routine laboratories due to its similarity to other species, such as *Providencia* spp. and *Proteus* spp., leading to a higher chance of misidentification. A study in Iraq reported a prevalence rate of 4%, which may be explained by their focus on high-risk patients, such as those with diabetes, trauma, catheterization, or elderly individuals [24]. The present study also found that 85.72% of *M. morganii* isolates came from the in-patient department, underscoring the hospital-acquired nature of most infections, a finding echoed by a study in China [25].

Urinary tract infections (UTIs) (42.85%) and wound infections (28.57%) were identified as the most common infections caused by *M. morganii*, which aligns with findings from China [26]. A study from Serbia reported a higher isolation rate from pus samples than urine, but this difference could be due to factors such as catheterization, which facilitates bacterial colonization in the urinary bladder, or the proximity to the perianal region, where *M. morganii* can colonize even in healthy individuals [4]. These factors may also explain the higher isolation rates from pus collected from lesions in the lower body. However, the current study did not record data on catheterization or pus collection sites. Male patients accounted for 71.42% of the *M. morganii* infections in this study, a finding consistent with studies from Taiwan, which reported a significant male predominance [27, 28]. The exact cause of this male predominance remains unclear, but it could be related to gender disparities in healthcare-seeking behaviors or increased trauma in males due to outdoor activities, resulting in more wound infections and hospitalizations. The antibiotic resistance patterns in this study revealed that *M. morganii* isolates exhibited maximum sensitivity to amikacin (42.85%) and imipenem (42.85%), which is consistent with findings from Iraq [10]. However, the study observed high resistance rates to cephalosporins, with 71.42% of isolates resistant to ceftriaxone, ceftazidime, cefepime, and ceftioxin.

This high resistance may be due to the presence of chromosomally mediated inducible  $\beta$ -lactamases, such as cephalosporinase and penicillinase, which lead to treatment failures despite initial susceptibility. Imipenem resistance was found in 57.14% of *M. morganii* isolates, with MICs ranging from 16 to 128  $\mu\text{g/ml}$ . This is consistent with a recent study from DMCH, which

reported 25% imipenem resistance in *Proteus mirabilis* isolates with similar MIC values [29]. A study from Nepal also reported similar MIC values for imipenem resistance [30]. The rising resistance to carbapenems may be attributed to the increased use of these drugs in response to high resistance rates in broad-spectrum cephalosporins and other  $\beta$ -lactam antibiotics. Amikacin resistance was found in 57.14% of *M. morganii* isolates, with MICs ranging from 256 to 2048  $\mu\text{g/ml}$ . A study at DMCH reported 68.18% resistance to amikacin in *Proteus mirabilis* isolates, with similar MIC values [29]. In contrast, a study in Iraq reported only 17.6% resistance to amikacin [24]. The increasing resistance in this study may be due to DMCH being a tertiary care hospital, where critically ill patients, including those in the ICU and burn units, are at higher risk of developing nosocomial infections and transmitting multidrug-resistant pathogens. Ceftazidime resistance was observed in 57.14% of *M. morganii* isolates, with MIC values ranging from 64 to 512  $\mu\text{g/ml}$ , similar to findings from Pakistan, where 60% of *M. morganii* isolates were resistant to ceftazidime [31]. In this study, 28.57% of *M. morganii* isolates were detected as ESBL producers by the DDS test. A study at DMCH detected 22.73% ESBL-producing *Proteus mirabilis*, a finding comparable to this study. A study at DMCH also found 38.46% ESBL-producing *Citrobacter freundii*, and a study in Pakistan reported 12% ESBL production in *M. morganii* [32-37]. The high prevalence of ESBL-producing strains in this study could be attributed to the indiscriminate and overuse of extended-spectrum antibiotics. The present study also detected the presence of ESBL encoding genes, including *bla*CTX-M and *bla*TEM, consistent with a study at DMCH, and findings from Iraq. However, no SHV ESBL gene was detected in the present study. In conclusion, this study highlights the emerging significance of *M. morganii* as a nosocomial pathogen in Bangladesh, with a notable prevalence of MDR strains. The findings emphasize the need for continued surveillance and the prudent use of antibiotics in hospital settings to mitigate the spread of resistant pathogens.

## CONCLUSION

*Morganella morganii* has emerged as a medically important pathogen because of the increasing multidrug resistance by this organism. This organism was most commonly isolated from urine and wound swab samples.

DNA sequences from PCR product was 95% identical with DNA sequences of 16S ribosomal RNA gene available at gene bank and phylogenetic tree showed *Morganella morganii* isolated in this study was clustered with *Morganella morganii* strain LMG 7874. *Morganella morganii* is resistant to commonly used antibiotics in the present study with increased resistance to imipenem. Resistance to imipenem is increasing due to production of carbapenemase enzyme. Among the phenotypic tests for carbapenemase detection, CD assay was found to be most sensitive and specific. Present study observed that combination therapy might serve as a good option for the treatment of MDR *Morganella morganii*. Ceftazidime plus amikacin and imipenem plus amikacin were the most effective combination, both in vitro and in vivo.

**Funding:** No funding sources

**Conflict of interest:** None declared

## REFERENCES

- Erlanger D, Assous MV, Wiener-Well Y, Yinnon AM, Ben-Chetrit E. Clinical manifestations, risk factors and prognosis of patients with *Morganella morganii* sepsis. *J Microbiol Immunol Infect.* 2019;52(3):443-448.
- Minnullina S, Gukasyan H, Kasyanov A. Genomic and antimicrobial resistance characterization of *Morganella morganii* strains from patients in Russia. *Front Microbiol.* 2021;12:642387. doi:10.3389/fmicb.2021.642387
- Liu X, Li Z, Wang J, Zhang L. Molecular epidemiology and antimicrobial resistance patterns of *Morganella morganii* isolates from patients in a Chinese hospital. *J Clin Microbiol.* 2016;54(5):1241-1246.
- Zaric D, Pasic S, Petrovic S. *Morganella morganii* as a causative agent of urinary tract infections: Antimicrobial susceptibility and molecular identification. *Med Arch.* 2021;75(4):274-278.
- Laupland KB, Gregson DB, Pitout JD. Community-associated urinary tract infections due to *Morganella morganii*. *Clin Infect Dis.* 2022;75(1):75-82.
- Bandy A. Ringing bells: *Morganella morganii* fights for recognition. *Public Health.* 2020;182:45-50.
- da Cunha Ferreira T, Martins IS. Risk factors of death in bloodstream infections caused by AmpC  $\beta$ -lactamase-producing enterobacteriales in patients with neoplasia. *Infect Drug Resist.* 2021;14:3083-3097.
- Tamma PD, Akenroye AT, Wilson SL. An overview of the molecular mechanisms behind the resistance of *Morganella morganii*. *Antimicrob Agents Chemother.* 2019;63(12):e01230-19.
- Moura LM, Martins M, De Oliveira JT. Antibiotic resistance and virulence determinants in *Morganella morganii*. *Antimicrob Resist Infect Control.* 2018;7(1):90.
- Al-Muhanna AS, Al-Muhanna S, Alzuhairi MA. Molecular investigation of extended-spectrum  $\beta$ -lactamase genes and potential drug resistance in clinical isolates of *Morganella morganii*. *Ann Saudi Med.* 2016;36(3):223-228.
- González LV. Human Pathogenic Enterobacteriales. 2022.
- Wu L, Chen L, Wang X. Resistance patterns of *Morganella morganii* and other Enterobacteriaceae in hospitalized patients. *J Clin Microbiol.* 2022;60(4):e01324-21.
- Learman L, Doughty M, Kim S. *Morganella morganii* infections in neonates: A multi-center study. *J Pediatr Infect Dis.* 2019;38(6):613-618.
- Brauer AL, White AN, Learman BS, Johnson AO, Armbruster CE. D-serine degradation by *Proteus mirabilis* contributes to fitness during single-species and polymicrobial catheter-associated urinary tract infection. *mSphere.* 2019;4(1):e01028-18.
- Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae infections: A systematic review. *Lancet Infect Dis.* 2016;10(1):43-50.
- Al-Quraini A, Rizvi M, Al-Jabri Z, Sami H, Al-Muzahmi M, Al-Muharrmi Z. Assessment of in-vitro synergy of fosfomycin with meropenem, amikacin, and tigecycline in whole genome sequenced extended and pan-drug resistant *Klebsiella pneumoniae*: Exploring a colistin-sparing protocol. *Antibiotics.* 2022;11(2):153.
- Mukherjee M, Das S, Banerjee A. Evaluation of resistance mechanisms and clinical outcomes in *Morganella morganii* bacteremia. *J Infect Public Health.* 2022;15(8):1105-1112.
- Behera DU, Ratnajothy K, Dey S, Gaur M, Sahoo RK, Sahoo S, et al. In vitro synergistic interaction of colistin and other antimicrobials against intrinsic colistin-resistant *Morganella morganii* isolates. *3 Biotech.* 2023;13(5):127.
- Ferri M, Ranucci E, Romagnoli P, Giaccone V. Antimicrobial resistance: A global emerging threat to public health systems. *Crit Rev Food Sci Nutr.* 2017;57(13):2857-2876.
- Meem FC, Shourove JH, Raihan T, Azad AK, Islam GR. Antibiotic resistance of ESBL-producing *E. coli* and

- other gram-negative bacteria isolated from street-vended foods in Bangladesh. *J Microbiol Biotechnol Food Sci.* 2024;13(6):e9429-e9429.
21. Munim MA, Das SC, Hossain MM, Hami I, Topu MG, Gupta SD. Multi-drug resistant (MDR) Gram-negative pathogenic bacteria isolated from poultry in the Noakhali region of Bangladesh. *PLoS One.* 2024;19(8):e0292638.
  22. Chen YT, Peng HL, Shia WC, Hsu FR, Ken CF, Tsao YM, et al. Whole-genome sequencing and identification of *Morganella morganii* KT pathogenicity-related genes. *BMC Genomics.* 2012;13:1-14.
  23. Yonggang Z, Ying L, Zhaoxin L, Li X, Lihong X, Shuwen W, et al. Evaluation of enrofloxacin in the Chinese soft-shelled turtle (*Pelodiscus sinensis*) based on the biochemical, histopathological and intestinal microbiota responses. *Pelodiscus Sinensis.* [Details incomplete].
  24. Said KB, Alsolami A, Khalifa AM, Khalil NA, Moursi S, Osman A, et al. A multi-point surveillance for antimicrobial resistance profiles among clinical isolates of gram-negative bacteria recovered from major Ha'il Hospitals, Saudi Arabia. *Microorganisms.* 2021;9(10):2024.
  25. Jean SS, Lee YL, Liu PY, Lu MC, Ko WC, Hsueh PR. Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018. *J Microbiol Immunol Infect.* 2022;55(3):463-473.
  26. Lee IK, Liu JW. Clinical characteristics and risk factors for mortality in *Morganella morganii* bacteremia. *J Microbiol Immunol Infect.* 2006;39(4):328-334.
  27. Munim MA, Das SC, Hossain MM, Hami I, Topu MG, Gupta SD. Multi-drug resistant (MDR) Gram-negative pathogenic bacteria isolated from poultry in the Noakhali region of Bangladesh. *PLoS One.* 2024;19(8):e0292638.
  28. Subedi M, Thapaliya S, Thapa S. Prevalence and antibiotic susceptibility pattern of uropathogens from urinary tract infection suspected patients visiting tertiary care hospital of Nepal. *Amrit Res J.* 2024;5(1):114-121.
  29. Xiang G, Lan K, Cai Y, Liao K, Zhao M, Tao J, et al. Clinical molecular and genomic epidemiology of *Morganella morganii* in China. *Front Microbiol.* 2021;12:744291.
  30. Patwari SQ. Transforming Rural Health: The Impact of Telehealth on Access and Care. *TAJ: Journal of Teachers Association.* 2021 Dec 31;34(2):51-56.
  31. Ahasan MM, Patwari MS, Yamaguchi M. Risk of eating disorders and the relationship with interest in modern culture among young female students in a university in Bangladesh: a cross-sectional study. *BMC Women's Health.* 2023;23(1):35.
  32. Patwari SQ. Public Health during the Global Pandemic Covid-19: Intervening, Perceiving and Incorporating.
  33. Hasan H, Rahman MH, Haque MA, Rahman MS, Ali MS, Sultana S. Nutritional management in patients with chronic kidney disease: A focus on renal diet. *Asia Pacific Journal of Medical Innovations.* 2024 ;1(1):34-40.
  34. Patwari SQ. Rise of E-Cigarettes: Implications for Public Health and Policy. *TAJ: Journal of Teachers Association.* 2017 Dec 31;30(2):43-51.
  35. Mashiusjaman M, Patwari SQ, Siddique MA, Haider SM. Infant feeding pattern of employed mothers in Dhaka city of Bangladesh.
  36. Patwari SQ. Bridging the Gap: Impact of Race, Gender, and Socioeconomic Factors on Health Equity. *TAJ: Journal of Teachers Association.* 2015 Dec 31;28(2):51-58.
  37. Farzana R. A genomic approach to understanding the molecular epidemiology and clinical burden of multi-drug resistant Enterobacterales infections in Bangladesh [dissertation]. Cardiff (UK): Cardiff University; 2020.